Jaguar Health Reports Third Quarter 2024 Financial Results
Portfolio Pulse from
Jaguar Health reported a 14% increase in Q3 2024 revenue compared to Q2 2024, driven by its cancer supportive care drug crofelemer and the launch of Gelclair. The company is advancing its clinical trials and will present significant trial results at the SABCS. An investor webcast is scheduled for November 13, 2024.
November 13, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health's Q3 2024 revenue increased by 14% due to its cancer supportive care drug crofelemer and the launch of Gelclair. The company is progressing with clinical trials and will present trial results at the SABCS.
The 14% revenue increase and the launch of a new product, Gelclair, are positive indicators for Jaguar Health. The upcoming presentation of trial results at a major symposium and the initiation of new trials further support a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100